James Liao Sells 1,943 Shares of Foxx Development (NASDAQ:FOXX) Stock

Posted by Francis Steltz on Jun 5th, 2026

Foxx Development Holdings Inc. (NASDAQ:FOXX – Get Free Report) CTO James Liao sold 1,943 shares of the company’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $6.15, for a total transaction of $11,949.45. Following the completion of the transaction, the chief technology officer directly owned 19,431 shares of the company’s stock, valued at approximately $119,500.65. The trade was a 9.09% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Foxx Development Stock Performance

NASDAQ FOXX traded down $0.19 on Friday, reaching $5.06. The company had a trading volume of 6,637,369 shares, compared to its average volume of 957,735. The firm has a market capitalization of $35.63 million, a price-to-earnings ratio of -0.74 and a beta of -0.31. Foxx Development Holdings Inc. has a 1-year low of $1.71 and a 1-year high of $8.88. The company’s fifty day moving average is $4.68 and its 200-day moving average is $4.52.

Foxx Development (NASDAQ:FOXX – Get Free Report) last posted its quarterly earnings data on Wednesday, May 20th. The company reported ($5.19) EPS for the quarter. The firm had revenue of $8.67 million for the quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings cut shares of Foxx Development from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Foxx Development currently has a consensus rating of “Sell”.

Read Our Latest Analysis on FOXX

Institutional Trading of Foxx Development

An institutional investor recently raised its position in Foxx Development stock. JPMorgan Chase & Co. grew its holdings in shares of Foxx Development Holdings Inc. (NASDAQ:FOXX – Free Report) by 170.9% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 4,947 shares of the company’s stock after acquiring an additional 3,121 shares during the period. JPMorgan Chase & Co. owned about 0.07% of Foxx Development worth $27,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 60.44% of the company’s stock.

Foxx Development Company Profile

(Get Free Report)

Foxx Development, Inc (NASDAQ: FOXX) operates as a contract manufacturer specializing in the design, assembly and distribution of medical devices and components. The company’s core business centers on phlebotomy and blood collection products, serving clinical laboratories, hospitals and diagnostic testing facilities. Its product portfolio includes evacuated blood collection tubes, safety-engineered winged blood collection sets, syringes and ancillary devices used in specimen collection and handling.

Founded in North Carolina, Foxx Development maintains a manufacturing and distribution campus in Apex, where it integrates engineering, quality control and regulatory compliance under one roof.